Pim-3 kinase as a target for type 2 diabetes mellitus
CA 2473566 C · Owner: Sanofi-Aventis Deutschland Gmbh · Inventors: Tschank, Georg; Mueller, Guenter; Schneider, Rudolf
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover the invention relates to a , polypeptide having PIM-3 activity and having a definite amino acid sequence as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 20, 2003 and granted May 1, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 20, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 20, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.